Biofrontera: 3 Key Takeaways for Long-Term Investors
Customs clearance for a redesigned lamp lets Biofrontera resume deliveries, but a going-concern warning means it must turn that access into cash.
Biofrontera's Ameluz receives FDA approval for treating superficial basal cell carcinoma, marking a second treatment indication for the light-activated topical gel. Dermatologists can administer the drug using red light illumination lamps already in their offices, allowing the company to grow prescription volume without expanding its commercial field team.
However, the company faces challenges, including a recent US Customs and Border Protection order allowing the redesign of its large-panel illumination lamp, which temporarily restricted drug sales to dermatology clinics. Additionally, rising legal fees and lamp remediation costs led to a decrease in cash and cash equivalents from $6.4 million at year-end 2025 to $3.2 million at the end of Q3 2026.
Management emphasizes the company's structural advantages, such as an installed base of 853 light devices across 742 clinics, enabling sales of new indications without the need for additional sales reps. The company is also actively pursuing a third label expansion for bodywide treatment of actinic keratosis while managing liquidity.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.